Dr. Reddy's gets Health Canada nod for generic Semaglutide Injection

Regulatory Product ApprovalBusiness Updates View source PDF Explain this filing

DRREDDY · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.5%Reaction day

₹1347.40

prior close

₹1367.00

announcement price

After-mkt

timing

Nifty 100market · index membership as recorded later (tracked since Jun 2026)+0.6%-2.1% vs market

Pharmaceuticals peers, median of 165sector+0.0%-1.5% vs sector

On the reaction day the stock moved 2.1 pts less than Nifty 100 and 1.5 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-2.0

10m

-2.5

15m

-1.9

30m

-1.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.5+0.6-2.1+0.0-1.5

Next day

-1.7-0.2-1.4-0.5-1.2

-4.4+0.3-4.7+0.0-4.4

-5.6+0.1-5.7+0.6-6.2

-2.9+1.4-4.4+2.4-5.3

-3.0+1.5-4.5+3.0-6.1

-4.9-0.7-4.2+3.3-8.1

15d

-2.0-1.4-0.6+2.7-4.7

-2.0-1.4-0.6+4.2-6.2

+2.4+0.1+2.3+5.1-2.7

-15.2+1.4-16.6+7.8-23.0

UpDownMarket · Nifty 100Sector · Pharmaceuticals peers, median of 165Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Dr. Reddy's received Health Canada approval (Notice of Compliance) for its generic Semaglutide Injection, used in type 2 diabetes treatment. Dr. Reddy's is the first company to secure marketing authorization for generic Semaglutide in Canada, granted ahead of the review target date. The approval covers 2 mg/pen and 4 mg/pen doses. Canada is the world's second-largest Semaglutide market, with ~3.9 million Canadians living with diagnosed diabetes. API is made in-house.

Likely market impact

Positive — first-mover advantage in Canada's large generic Semaglutide market; strengthens regulated-market diabetes portfolio and revenue potential.